clinical trial · NCT07271667
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Curis, Inc.·phase2·recruiting·n = 108
Chronic Lymphocytic LeukemiaB-cell MalignanciesEmavusertibZanubrutinib
brief summary
The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.
started
Apr 23, 2026
primary completion
Nov 1, 2027
completion
Nov 1, 2027
last updated
Jun 12, 2026
official title
A Phase 2 Study of Emavusertib in Combination With an Approved Bruton Tyrosine Kinase Inhibitor in Patients With Chronic Lymphocytic Leukemia and Other B-cell Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol